Related Experiment Video
Updated: Sep 27, 2025
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
The Relevance of Aurora Kinase Inhibition in Hematological Malignancies
Caio Bezerra Machado1, Emerson Lucena DA Silva1, Beatriz Maria Dias Nogueira1
1Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM),Federal University of Ceará, Fortaleza, CE, Brazil.
Abstract:
Aurora kinases are a family of serine/threonine protein kinases that play a central role in eukaryotic cell division. Overexpression of aurora kinases in cancer and their role as major regulators of the cell cycle quickly inspired the idea that their inhibition might be a potential pathway when treating oncologic patients. Over the past couple of decades, the search for designing and testing of molecules capable of inhibiting aurora activities fueled many pre-clinical and clinical studies. In this study, data from the past 10 years of in vitro and in vivo investigations, as well as clinical trials, utilizing aurora kinase inhibitors as therapeutics for hematological malignancies were compiled and discussed, aiming to highlight potential uses of these inhibitors as a novel monotherapy model or alongside conventional chemotherapies. While there is still much to be elucidated, it is clear that these kinases play a key role in oncogenesis, and their manageable toxicity and potentially synergistic effects still render them a focus of interest for future investigations in combinatorial clinical trials.
Insights
Aurora kinase inhibitors show promise for treating blood cancers by targeting cell division. Further research is exploring their use alone or with chemotherapy for better cancer treatment outcomes.
Area of Science:
- Biochemistry
- Oncology
- Cell Biology
Background:
- Aurora kinases are crucial serine/threonine protein kinases regulating eukaryotic cell division.
- Their overexpression in cancer and role in cell cycle control suggest therapeutic potential.
- Inhibitors targeting aurora kinase activity have been extensively studied pre-clinically and clinically.
Purpose of the Study:
- To review and discuss data from the last decade on aurora kinase inhibitors in hematological malignancies.
- To evaluate their potential as monotherapy or in combination with conventional treatments.
- To highlight future research directions for these inhibitors in clinical trials.
Main Methods:
- Compilation and analysis of in vitro and in vivo investigation data.
- Review of clinical trial outcomes for aurora kinase inhibitors.
- Focus on hematological malignancies over the past 10 years.
Main Results:
- Aurora kinase inhibitors demonstrate potential in treating hematological malignancies.
- Manageable toxicity profiles observed for these inhibitors.
- Evidence of potentially synergistic effects when combined with other therapies.
Conclusions:
- Aurora kinases are key players in oncogenesis, making them attractive therapeutic targets.
- Aurora kinase inhibitors offer a promising avenue for novel monotherapy or combination strategies.
- Continued investigation in combinatorial clinical trials is warranted due to their potential and manageable toxicity.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
01:22PI3K/mTOR/AKT Signaling Pathway
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...